<DOC>
	<DOCNO>NCT02992808</DOCNO>
	<brief_summary>In study investigator try discover whether difference stimulation preparation - recombinant FSH + recombinant LH ( pergoveris &amp; luveris ) vs. human menopausal gonadotropin ( menopur ) GnRH-antagonist cycle mean androgenic hormone profile . The study question whether use recombinant LH result different follicular hormonal milieu , serum endocrine profile IVF outcomes use highly purify urinary gonadotropin hCG mimic LH activity .</brief_summary>
	<brief_title>Androgenic Profile Following Controlled Ovarian Stimulation</brief_title>
	<detailed_description>ABSTRACT : The optimal control ovarian stimulation ( COH ) protocol yet decide probably right protocol optimal patient . The role luteinizing hormone ( LH ) administration control ovarian stimulation ( COH ) widely debate current medical literature . Until recently source exogenous LH activity HMG preparation , however , past year advancement field recombinant technology result recombinant preparation LH . In contrast LH activity HMG mainly due hCG rather LH , use r-LH provide true , consistent precise LH activity . In past year paper publish difference recombinant follicle stimulate hormone ( r-FSH ) menotropins still need research different effect gonadotropin preparation particular effect LH administration COH manner follicular endocrine characteristic , embryo quality pregnancy outcome . In present study investigator aim elucidate whether difference stimulation preparation - recombinant FSH + recombinant LH ( pergoveris &amp; luveris ) vs. human menopausal gonadotropin ( menopur ) GnRH-antagonist cycle . The study question whether use recombinant LH result different follicular hormonal milieu , serum endocrine profile IVF outcomes use highly purify urinary gonadotropin hCG mimic LH activity . In relevant medical literature one prospective study deal question , , long-GnRH-agonist cycle . In aforementioned paper significant difference two stimulation preparation . MATERIALS &amp; METHODS : Study design - A non-intervention observational trial . Primary endpoint - Serum &amp; follicular fluid hormonal profile COH ( FSH , LH , progesterone , estradiol , testosterone , androstendione , 17-OH progesterone ) Secondary endpoint - Implantation rate , clinical pregnancy , # follicle , # oocyte , # embryo , top quality embryo . Study sample - 100 patient undergoing COH IVF use GnRH-antagonist protocol Inclusion criterion - 20-40 year old IVF patient , BMI 19-35 undergo 1-4 IVF cycle . Exclusion criterion - Suspected PCOS , history OHSS , Patients chronic illness receive chronic medical treatment exclude . Gonadotropin preparation - 1 . As HP-HMG use Menopur© ( menotropins injection , FERRING ) contain equal amount FSH &amp; LH . 2 . As recombinant preparation use Pergoveris© ( follitropin alfa/lutropin alfa , MERCK SERONO ) contain 150 unit FSH + 75 unit LH Luveris© ( lutropin alfa , MERCK SERONO ) LH preparation . The patient - The study population consist consecutive eligible patient attend IVF unit department treatment infertility . The study require modification routine , flexible , multi-dose GnRH antagonist protocol . Briefly , presence quiescent ovaries transvaginal ultrasound low serum E2 level confirm day 2/3 menstruation , recombinant FSH - Gonal-F© ( follitropin alfa ; MERCK SERONO ) administer subcutaneously start dose 150-300 IU , depend patient 's age and/or ovarian responsiveness previous cycle . The gonadotropin dosage adjust individually accord serum E2 level vaginal ultrasound measurement follicular diameter , obtain every one two day . LH add protocol urinary preparation Menopur© ( menotropins injection , FERRING ) recombinant preparation - Pergoveris© ( follitropin alfa/lutropin alfa , MERCK SERONO ) without Luveris© ( lutropin alfa , MERCK SERONO ) . GnRH-antagonist - Cetrotide© ( cetrorelix , MERCK SERONO ) , 0.25 mg daily subcutaneously , add leading follicle reach 14-16 mm diameter , continue day ovulation trigger . When least three mature ( &gt; 17 mm ) follicle obtain , patient receive injection either Ovitrelle© 250 mcg ( Choriogonadotropin alfa , MERCK SERONO ) GnRH-agonist - Decapeptyl© 0.2 mg ( Triptorelin acetate , FERRING ) . In summary , purpose study , addition routine monitoring COH cycle , blood sample draw determine hormonal profile ( E2 , progesterone ) , level serum androgen , namely , testosterone , androstendione , 17-OH progesterone LH FSH : ( 1 ) day 1-3 menstruation ( Day-S ) ; ( 2 ) day prior hCG administration ( Day-hCG ) ; ( 3 ) day ovum pick-up ( Day-OPU ) . Moreover , pool follicular fluid collect oocyte retrieval ( fluid destine discard ) examine hormonal profile ( FSH , LH , progesterone , estradiol , testosterone , androstendione , 17-OH progesterone ) . To note - participation study WILL NOT change COH treatment . Statistics - The chi-squared test analysis variance ( ANOVA ) apply detect statistically significant difference among group regard proportion mean . A two-sided P &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<criteria>Infertile woman 2040 year age BMI 1935 undergo 14 IVF cycle Suspected PCOS History OHSS Patients chronic illness receive chronic medical treatment</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>IVF</keyword>
	<keyword>Ovarian stimulation</keyword>
	<keyword>Androgenic profile</keyword>
	<keyword>Follicular fluid</keyword>
	<keyword>Recombinant gonadotropin</keyword>
	<keyword>human menopausal gonadotropin</keyword>
</DOC>